Showing results (101-110 of 186) with videos related to
Sort By:
Pageof 19
Cancer|November 29, 2024
The incidence of pancreatic cancer in women with a BRCA1 or BRCA2 mutationBryson W Katona, Jan Lubinski, Tuya Pal, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 27, 2022
Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A ReappraisalJoanne Kotsopoulos, Jan Lubinski, Jacek Gronwald, et al.BMC Cancer|November 11, 2025
Treatment of infertility and risk of breast cancer among women with a BRCA pathogenic variant: a matched case-control studyMarta Seca, Jacek Gronwald, Tomasz Huzarski, et al.Breast Cancer Research : BCR|November 18, 2010
Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancersNadine Tung, Alexander Miron, Stuart J Schnitt, et al.Breast Cancer Research and Treatment|February 25, 2010
Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriersSusan M Domchek, Tara M Friebel, Judy E Garber, et al.Gynecologic Oncology|August 22, 2024
Incidence of endometrial cancer in BRCA mutation carriersJoanne Kotsopoulos, Jan Lubinski, Tomasz Huzarski, et al.Gynecologic Oncology|August 10, 2025
Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variantAdriana I Apostol, Joanne Kotsopoulos, Jacek Gronwald, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 9, 2012
Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriersJoanne Kotsopoulos, Jan Lubinski, Henry T Lynch, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2014
Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutationAmy P M Finch, Jan Lubinski, Pål Møller, et al.Breast Cancer Research and Treatment|June 22, 2014
Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriersJacek Gronwald, Andre Robidoux, Charmaine Kim-Sing, et al.Pageof 19